摘要
目的分析32例原发性肝癌患者介入治疗前后血清上皮钙粘蛋白(E-cad)和SIL-2R含量的变化及临床意义。方法采用酶联法测定血清上皮钙粘蛋白和SIL-2R含量,并与35例正常对照作对比。结果原发性肝癌患者介入治疗前血清上皮钙粘蛋白和SIL-2R水平显著高于对照组(P<0.01),介入治疗后6个月复发者血清上皮钙粘蛋白和SIL-2R水平持续异常,未复发者血清上皮钙粘蛋白和SIL-2R水平恢复正常。结论E-cad和SIL-2R的变化与原发性肝病病情和预后密切相关。
Objective To analyze the levels of E-cad and SIL-2R in 32 patients with primary liver cancer before and after interventions[ therapy. Method Serum E-cad and SIL-2R were detected hy ELTSA in 32 patients with primary liver cancer and compared with those in 35 normal controls. Results Before interventional therapy serum E-cad and SIL-2R levels were higher than those in normsl controls （P〈0.01）. The levels of E-cad and SIL-2R were continualy abnormal in recurrent potients after interventionsl therapy for six months. The levels of E-cad and SIL-2R were normal in patients without recurnent after interventional therapy. Conclusion The variety of E-cad and SIL-2R associated with disease condition and prognosis of the primary liver cancer.
出处
《临床输血与检验》
CAS
2006年第2期114-115,共2页
Journal of Clinical Transfusion and Laboratory Medicine
